Chronic oral administration of Ang-(1-7) improves skeletal muscle, autonomic and locomotor phenotypes in muscular dystrophy

Clinical Science

Volumn 127, Issue 2, 2014, Pages 101-109

  Sabharwal, Rasna ^a   Cicha, Michael Z ^b   Sinisterra, Ruben D M ^c   de Sousa, Frederico B ^d   Santos, Robson A ^c   Chapleau, Mark W ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d FEDERAL UNIVERSITY OF ITAJUBÁ   (Brazil)

Author keywords

ACE2 Ang (1 7) Mas axis; Autonomic regulation; Dystrophin glycoprotein complex; Neuromuscular disorder; Renin angiotensin system (RAS); Sarcoglycan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN[1-7]; BETA CYCLODEXTRIN; COLLAGEN TYPE 3; FIBRONECTIN; RECEPTOR; RECEPTOR MAS; UNCLASSIFIED DRUG; ANGIOTENSIN I; ANGIOTENSIN I (1-7); DYSTROPHIN; PEPTIDE FRAGMENT; SARCOGLYCAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTONOMIC DYSFUNCTION; BLOOD PRESSURE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEART RATE; IMMUNOFLUORESCENCE; LOCOMOTION; MALE; MOUSE; MUSCULAR DYSTROPHY; MYOFIBROSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VAGUS TONE; ANIMAL; C57BL MOUSE; DRUG EFFECTS; FIBROSIS; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOTOR ACTIVITY; MUSCULAR DYSTROPHIES; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; SKELETAL MUSCLE;

ADMINISTRATION, ORAL; ANGIOTENSIN I; ANIMALS; DYSTROPHIN; FIBROSIS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES; PEPTIDE FRAGMENTS; PHENOTYPE; SARCOGLYCANS;

EID: 84897499915     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20130602     Document Type: Article

References (50)

1. Heydemann A. and McNally E. M. (2007) Consequences of disrupting the dystrophin-sarcoglycan complex in cardiac and skeletal myopathy. Trends Cardiovasc. Med. 17, 55-59.
2. Coral-Vazquez R., Cohn R. D., Moore S. A., Hill J. A., Weiss R. M., Davisson R. L., Straub V., Barresi R., Bansal D., Hrstka R. F. et al. (1999) Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell 98, 465-474.
3. Lapidos K. A., Kakkar R. and McNally E. M. (2004) The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ. Res. 94, 1023-1031.
4. Politano L., Palladino A., Nigro G., Scutifero M. and Cozza V. (2008) Usefulness of heart rate variability as a predictor of sudden cardiac death in muscular dystrophies. Acta Myol. 27, 114-122.
5. Inoue M., Mori K., Hayabuchi Y., Tatara K. and Kagami S. (2009) Autonomic function in patients with Duchenne muscular dystrophy. Pediatr. Int. 51, 33-40.
6. Matsusaka T. and Ichikawa I. (1997) Biological functions of angiotensin and its receptors. Annu. Rev. Physiol. 59, 395-412.
7. Ferreira A. J., Santos R. A., Bradford C. N., Mecca A. P., Sumners C., Katovich M. J. and Raizada M. K. (2010) Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension 55, 207-213.
8. Ferreira A. J. and Santos R. A. (2005) Cardiovascular actions of angiotensin-(1-7). Braz. J. Med. Biol. Res. 38, 499-507.
9. Santos R. A., Simoes e Silva A. C., Maric C., Silva D. M., Machado R. P., de Buhr I., Heringer-Walther S., Pinheiro S. V., Lopes M. T., Bader M. et al. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U.S.A. 100, 8258-8263.
10. Ferrario C. M., Chappell M. C., Tallant E. A., Brosnihan K. B. and Diz D. I. (1997) Counterregulatory actions of angiotensin-(1-7). Hypertension 30, 535-541.
11. Santos R. A., Ferreira A. J. and Simoes e Silva A. C. (2008) Recent advances in the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis. Exp. Physiol. 93, 519-527.
12. Sabharwal R., Weiss R. M. and Chapleau M. W. (2010) Dysautonomia precedes cardiomyopathy in a mouse model of muscular dystrophy. Clin. Auton. Res. 20, 51-52.
13. Sabharwal R., Weiss R. M., Zimmerman K. and Chapleau M. W. (2010) Angiotensin II contributes to skeletal muscle fibrosis, reduced locomotor activity and autonomic dysfunction in δ-sarcoglycan deficient mice with muscular dystrophy. Hypertension 56, E103.
14. Sun G., Haginoya K., Dai H., Chiba Y., Uematsu M., Hino-Fukuyo N., Onuma A., Iinuma K. and Tsuchiya S. (2009) Intramuscular renin-angiotensin system is activated in human muscular dystrophy. J. Neurol. Sci. 280, 40-48.
15. Cabello-Verrugio C., Morales M. G., Cabrera D., Vio C. P. and Brandan E. (2012) Angiotensin II receptor type 1 blockade decreases CTGF/CCN2-mediated damage and fibrosis in normal and dystrophic skeletal muscles. J. Cell. Mol. Med. 16, 752-764.
16. Cohn R. D., van Erp C., Habashi J. P., Soleimani A. A., Klein E. C., Lisi M. T., Gamradt M., ap Rhys C. M., Holm T. M., Loeys B. L. et al. (2007) Angiotensin II type 1 receptor blockade attenuates TGF-β-induced failure of muscle regeneration in multiple myopathic states. Nat. Med. 13, 204-210.
17. Lula I., Denadai A. L., Resende J. M., de Sousa F. B., de Lima G. F., Pilo-Veloso D., Heine T., Duarte H. A., Santos R. A. and Sinisterra R. D. (2007) Study of angiotensin-(1-7) vasoactive peptide and its β-cyclodextrin inclusion complexes: complete sequence-specific NMR assignments and structural studies. Peptides 28, 2199-2210.
18. Sabharwal R., Zhang Z., Lu Y., Abboud F. M., Russo A. F. and Chapleau M. W. (2010) Receptor activity-modifying protein 1 increases baroreflex sensitivity and attenuates angiotensin-induced hypertension. Hypertension 55, 627-635.
19. Lu Y., Ma X., Sabharwal R., Snitsarev V., Morgan D., Rahmouni K., Drummond H. A., Whiteis C. A., Costa V., Price M. et al. (2009) The ion channel ASIC2 is required for baroreceptor and autonomic control of the circulation. Neuron 64, 885-897.
20. Gundersen H. J. and Jensen E. B. (1985) Stereological estimation of the volume-weighted mean volume of arbitrary particles observed on random sections. J. Microsc. 138, 127-142.
21. Klingler W., Jurkat-Rott K., Lehmann-Horn F. and Schleip R. (2012) The role of fibrosis in Duchenne muscular dystrophy. Acta Myol. 31, 184-195.
22. Lorts A., Schwanekamp J. A., Baudino T. A., McNally E. M. and Molkentin J. D. (2012) Deletion of periostin reduces muscular dystrophy and fibrosis in mice by modulating the transforming growth factor-β pathway. Proc. Natl. Acad. Sci. U.S.A. 109, 10978-10983.
23. Tidball J. G. and Wehling-Henricks M. (2007) The role of free radicals in the pathophysiology of muscular dystrophy. J. Appl. Physiol. 102, 1677-1686.
24. Gao L., Wang W., Li Y., Schultz H. D., Liu D., Cornish K. G. and Zucker I. H. (2005) Sympathoexcitation by central ANG II: Roles for AT1 receptor upregulation and NAD(P)H oxidase in RVLM. Am. J. Physiol. Heart Circ. Physiol. 288, H2271-H2279.
25. Morales M. G., Vazquez Y., Acuna M. J., Rivera J. C., Simon F., Salas J. D., Alvarez Ruf J., Brandan E. and Cabello-Verrugio C. (2012) Angiotensin II-induced pro-fibrotic effects p38MAPK activity and transforming growth factor β1 expression in skeletal muscle cells. Int. J. Biochem. Cell. Biol. 44, 1993-2002.
26. Thomas G. D., Sander M., Lau K. S., Huang P. L., Stull J. T. and Victor R. G. (1998) Impaired metabolic modulation of α-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc. Natl. Acad. Sci. U.S.A. 95, 15090-15095.
27. Della Marca G., Frusciante R., Scatena M., Dittoni S., Testani E., Vollono C., Losurdo A., Scarano E., Colicchio S., Farina B. et al. (2010) Heart rate variability in facioscapulohumeral muscular dystrophy. Funct. Neurol. 25, 211-216.
28. Hampton T. G., Kale A., McCue S., Bhagavan H. N. and Vandongen C. (2012) Developmental changes in the ECG of a hamster model of muscular dystrophy and heart failure. Front. Pharmacol. 3, 80.
29. Duboc D., Meune C., Lerebours G., Devaux J. Y., Vaksmann G. and Becane H. M. (2005) Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J. Am. Coll. Cardiol. 45, 855-857.
30. Reid I. A. (1992) Interactions between ANG II, sympathetic nervous system and baroreceptor reflexes in regulation of blood pressure. Am. J. Physiol. 262, E763-E778.
31. Ferguson A. V. and Bains J. S. (1997) Actions of angiotensin in the subfornical organ and area postrema: implications for long term control of autonomic output. Clin. Exp. Pharmacol. Physiol. 24, 96-101.
32. Diz D. I., Kasper S. O., Sakima A. and Ferrario C. M. (2007) Aging and the brain renin-angiotensin system: insights from studies in transgenic rats. Cleve. Clin. J. Med. 74 Suppl. 1, S95-S98.
33. Delliaux S., Brerro-Saby C., Steinberg J. G. and Jammes Y. (2009) Reactive oxygen species activate the group IV muscle afferents in resting and exercising muscle in rats. Pflugers Arch. 459, 143-150.
34. Kaufman M. P. (2012) The exercise pressor reflex in animals. Exp. Physiol. 97, 51-58.
35. Piepoli M. F., Dimopoulos K., Concu A. and Crisafulli A. (2008) Cardiovascular and ventilatory control during exercise in chronic heart failure: role of muscle reflexes. Int. J. Cardiol. 130, 3-10.
36. Koba S., Gao Z. and Sinoway L. I. (2009) Oxidative stress and the muscle reflex in heart failure. J. Physiol. 587.21, 5227-5237.
37. Patil J., Schwab A., Nussberger J., Schaffner T., Saavedra J. M. and Imboden H. (2010) Intraneuronal angiotensinergic system in rat and human dorsal root ganglia. Regul. Pept. 162, 90-98.
38. Pavel J., Tang H., Brimijoin S., Moughamian A., Nishioku T., Benicky J. and Saavedra J. M. (2008) Expression and transport of angiotensin II AT1 receptors in spinal cord, dorsal root ganglia and sciatic nerve of the rat. Brain. Res. 1246, 111-122.
39. Mederos y Schnitzler M., Storch U. and Gudermann T. (2011) AT1 receptors as mechanosensors. Curr. Opin. Pharmacol. 11, 112-116.
40. Katovich M. J., Grobe J. L. and Raizada M. K. (2008) Angiotensin-(1-7) as an antihypertensive, antifibrotic target. Curr. Hypertens. Rep. 10, 227-232.
41. Shenoy V., Ferreira A. J., Qi Y., Fraga-Silva R. A., Diez-Freire C., Dooies A., Jun J. Y., Sriramula S., Mariappan N., Pourang D. et al. (2010) The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am. J. Respir. Crit. Care. Med. 182, 1065-1072.
42. McCollum L. T., Gallagher P. E. and Tallant E. A. (2012) Angiotensin-(1-7) attenuates angiotensin II-induced cardiac remodeling associated with upregulation of dual-specificity phosphatase 1. Am. J. Physiol. Heart Circ. Physiol. 302, H801-H810.
43. Shaltout H. A., Westwood B. M., Averill D. B., Ferrario C. M., Figueroa J. P., Diz D. I., Rose J. C. and Chappell M. C. (2007) Angiotensin metabolism in renal proximal tubules, urine and serum of sheep: evidence for ACE2-dependent processing of angiotensin II. Am. J. Physiol. Renal. Physiol. 292, F82-F91.
44. Acuna M. J., Pessina P., Olguin H., Cabrera D., Vio C. P., Bader M., Munoz-Canoves P., Cabello-Verrugio C. and Brandan E. (2014) Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-β signalling. Hum. Mol. Genet. 23, 1237-1249.
45. Munoz M. C., Giani J. F., Burghi V., Mayer M. A., Carranza A., Taira C. A. and Dominici F. P. (2012) The Mas receptor mediates modulation of insulin signaling by angiotensin-(1-7). Regul. Pept. 177, 1-11.
46. Prasannarong M., Santos F. R. and Henriksen E. J. (2012) ANG-(1-7) reduces ANG II-induced insulin resistance by enhancing Akt phosphorylation via a Mas receptor-dependent mechanism in rat skeletal muscle. Biochem. Biophys. Res. Commun. 426, 369-373.
47. Marcus Y., Shefer G., Sasson K., Kohen F., Limor B., Pappo O., Nevo N., Biton I., Bach M., Berkutzki T. et al. (2013) Angiotensin 1-7 as means to prevent the metabolic syndrome: Lessons from the fructose-fed rat model. Diabetes 62, 1121-1130.
48. Benter I. F., Yousif M. H., Cojocel C., Al-Maghrebi M. and Diz D. I. (2007) Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am. J. Physiol. Heart Circ. Physiol. 292, H666-H672.
49. Gironacci M. M., Vatta M., Rodriguez-Fermepin M., Fernandez B. E. and Pena C. (2000) Angiotensin-(1-7) reduces norepinephrine release through a nitric oxide mechanism in rat hypothalamus. Hypertension 35, 1248-1252.
50. Guimaraes P. S., Santiago N. M., Xavier C. H., Velloso E. P., Fontes M. A., Santos R. A. and Campagnole-Santos M. J. (2012) Chronic infusion of angiotensin-(1-7) into the lateral ventricle of the brain attenuates hypertension in DOCA-salt rats. Am. J. Physiol. Heart Circ. Physiol. 303, H393-H400.